Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Megan Ann McNamara"'
Autor:
Devika Das, Terry Hyslop, Steven R. Patierno, Guru Sonpavde, Bonnie LaCroix, Tian Zhang, Brendon M. Patierno, Julia Rasmussen, Andrew J. Armstrong, A. Oliver Sartor, Patrick Healy, Kouros Owzar, James D. Bearden, Jennifer A. Freedman, Michael Moses Goodman, Kellie Shobe, Matthew I. Milowsky, Mark D. Fleming, Megan Ann McNamara, Michael R. Harrison, Julie Kephart, William R. Berry, Rhonda Wilder, Monika Anand, Carol Winters, Rick A. Kittles, Rhonda L. Bitting, Dadong Zhang, Colleen Riggan, Daniel J. George, Alexander B. Sibley, Elisabeth I. Heath, Susan Halabi
Publikováno v:
Cancer
BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pre
Publikováno v:
American Journal of Clinical Oncology. 42:399-406
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administrat
Autor:
Zev Nakamura, Allison Mary Deal, Eliza Myung Park, Kate Stanton, Yesy Lopez, Laura J. Quillen, Erin O'Hare Kelly, Hillary M Heiling, Kirsten A. Nyrop, Emily Miller Ray, Elizabeth Claire Dees, Katherine Elizabeth Reeder-Hayes, Trevor Augustus Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Megan Ann McNamara, Tim Ahles, Hyman B. Muss
Publikováno v:
Journal of Clinical Oncology. 40:12109-12109
12109 Background: Up to 75% of patients with breast cancer report cognitive decline following chemotherapy. There is no standard of care prevention or treatment of cognitive problems in these patients. This trial (NCT04033419) examines the feasibilit
Autor:
Chandra Rao, Monika Anand, Elizabeth Bronson, Kathryn E. Ware, Anika Agarwal, Daniella Runyambo, Andrew J. Armstrong, Jason A. Somarelli, Patrick Healy, Tian Zhang, Megan Ann McNamara, Daniel J. George, Rengasamy Boominathan, Taofik Oyekunle, R. Garland Almquist, Sally S.E. Park
Publikováno v:
Biomarker Research
Biomarker Research, Vol 9, Iss 1, Pp 1-12 (2021)
Biomarker Research, Vol 9, Iss 1, Pp 1-12 (2021)
BackgroundA subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTCs) for expression of immune che
Autor:
Yuan Wu, Rajan T. Gupta, Michael R. Harrison, Daniel J. George, Andrew J. Armstrong, Michael S. Humeniuk, Tian Zhang, Patrick Healy, Sundhar Ramalingam, Megan Ann McNamara
Publikováno v:
Prostate Cancer and Prostatic Diseases. 21:92-99
Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists as a s
Autor:
Chester Kao, Neil L. Spector, Tian Zhang, Jason Zhu, Megan Ann McNamara, Chris Alley, Shekeab Jauhari, Rajan T. Gupta
Publikováno v:
Clinical genitourinary cancer. 17(3)
Autor:
Daniel J. George, Lindsey Shantzer, Aseem Anand, Jorge Oldan, Andrew J. Armstrong, Monika Anand, Taofik Oyekunle, Michala Ritz, Megan Ann McNamara, Bennett B. Chin
Publikováno v:
The Prostate. 79(10)
Background Radium-223 improves survival and time to first symptomatic skeletal event in symptomatic bone predominant metastatic castrate-resistant prostate cancer (mCRPC). The imaging response to radium-223 has not been well characterized. Methods To
Autor:
Raoul S. Concepcion, Andrew J. Armstrong, Yuan Wu, Michael R. Harrison, Monika Anand, Megan Ann McNamara, Neal D. Shore, Ron Tutrone, Daniel J. George, Igor Dumbudze, Joe A. Wallace, Patrick Healy, Coleman D. Breland, Eda K. Holl
Publikováno v:
Prostate Cancer and Prostatic Diseases
Background Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month
Autor:
Tian Zhang, Escarleth Fernandez, Patrick Healy, Bridget F. Koontz, Colleen Riggan, Megan Ann McNamara, Yuan Wu, Rhonda Wilder, Luke T. Nordquist, Bart Frizzell, Taofik Oyekunle, Rhonda L. Bitting, Scott T. Tagawa, Himanshu Nagar, Monika Anand, Andrew J. Armstrong, Julia Rasmussen, Carolyn Winters, Michael R. Harrison, Daniel J. George
Publikováno v:
Journal of Clinical Oncology. 39:90-90
90 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortening but intensifying systemic therapy may improve outc
Publikováno v:
Evidence-Based Urology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13f39364c4eef273e8b8986f962fd668
https://doi.org/10.1002/9781119129875.ch28
https://doi.org/10.1002/9781119129875.ch28